-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
US officials, NGOs cry foul as Washington snubs UN rights review
-
Injured teen medal hope Tabanelli risks missing home Winter Olympics
-
Bellingham, Foden recalled to England squad for World Cup qualifiers
-
Tanzania rights group condemns 'reprisal killings' of civilians
-
Slot urges patience as Isak returns to training with Liverpool
-
Rees-Zammit set for Wales return with bench role against Argentina
-
China's new aircraft carrier enters service in key move to modernise fleet
-
Operation Cloudburst: Dutch train for 'water bomb' floods
-
Leaders turn up the heat on fossil fuels at Amazon climate summit
-
US travel woes mount as govt shutdown prompts flight cuts
-
North Korea fires unidentified ballistic missile: Seoul military
-
West Bank's ancient olive tree a 'symbol of Palestinian endurance'
-
Global tech tensions overshadow Web Summit's AI and robots
-
Green shines as Suns thump Clippers 115-102
-
Japan to screen #MeToo film months after Oscar nomination
-
Erasmus relishing 'brutal' France re-match on Paris return
-
Rejuvenated Vlahovic taking the reins for Juve ahead of Turin derby
-
'Well-oiled' Leipzig humming along in Bayern's slipstream
-
Bangladesh cricket probes sexual harassment claims
-
NFL-best Broncos edge Raiders to win seventh in a row
-
Deadly Typhoon Kalmaegi ravages Vietnam, Philippines
-
Three killed in new US strike on alleged drug boat, toll at 70
-
Chinese microdrama creators turn to AI despite job loss concerns
-
Trump hails Central Asia's 'unbelievable potential' at summit
-
Kolya, the Ukrainian teen preparing for frontline battle
-
Big leap in quest to get to bottom of climate ice mystery
-
Markets drop as valuations and US jobs, rates spook investors
-
'Soap opera on cocaine': how vertical dramas flipped Hollywood
-
Under pressure? EU states on edge over migrant burden-sharing
-
US influencers falsely associate Mamdani with extremist group
-
Hungary's Orban to meet Trump in face of Russia oil sanctions
-
US facing travel chaos as flights cut due to govt shutdown
-
Liverpool and Man City renew rivalry as they try to narrow Arsenal gap
-
UK's Andrew asked to testify over Epstein as he formally loses titles
-
Local hero: 'DC sandwich guy' found not guilty of assaulting officer with sub
-
Dead famous: Paris puts heritage graves up for grabs
-
UK grandmother on Indonesia death row flies home
-
Former NFL star Brown extradited from Dubai to face trial in shooting - police
-
Primary Hydrogen Identifies Two High-Priority Ree Anomaly Clusters from Geophysical and Soil Sampling Survey at Wicheeda North Project
-
How to Sell Your Small Business Fast (Guide Release)
-
Chile presidential hopeful vows to expel 'criminal' migrants to El Salvador
-
Trump event paused in Oval Office when guest faints
-
NFL Colts add Sauce to recipe while Patriots confront Baker
-
Home owned by Miami Heat coach Spoelstra damaged by fire
-
Tesla shareholders approve Musk's $1 trillion pay package
-
World leaders launch fund to save forests, get first $5 bn
-
Villa edge Maccabi Tel Aviv in fraught Europa League match
-
Protests as Villa beat Maccabi Tel Aviv under tight security
-
US Supreme Court backs Trump admin's passport gender policy
Bosses resign at Japan supplement firm probing deaths
The chairman and president of a major Japanese dietary supplement maker announced their resignation on Tuesday, as the company probes 80 deaths potentially linked to tablets meant to lower cholesterol.
Kobayashi Pharmaceutical is at the centre of a health scare linked to its over-the-counter tablets containing red yeast rice, which is fermented with a mould culture.
Medical studies say red yeast rice or "beni koji" can improve cholesterol levels but also warn of a risk of organ damage depending on the ingredient's chemical make-up.
A company statement said president Akihiro Kobayashi and chairman Kazumasa Kobayashi were leaving their posts. Both men belong to the firm's founding family.
The decision was made "to clarify executive responsibility over a series of actions by our company related to the 'beni koji' issue", Kobayashi Pharmaceutical said.
Red yeast rice has been used in food, alcoholic drinks and folk medicine for centuries around East Asia.
The scandal erupted in March when the company, a household name in Japan, recalled three brands of dietary supplements after customers complained of kidney problems.
It later said it had detected a potentially toxic acid produced by the mould at one of its factories, and the government inspected the firm's facilities.
Last month, the company said it was probing a total of 80 deaths possibly connected to its pills, and investigating whether organs other than kidneys were harmed.
But at the time the government called Kobayashi Pharmaceutical's delay in reporting the number of cases under investigation "extremely regrettable".
On Tuesday, the company's board of directors said in a separate statement that they "pray for the souls of those who died... and offer condolences to the bereaved families".
The company's new president is Satoshi Yamane, previously head of sustainability policy, the company said.
Outgoing president Akihiro Kobayashi, who has expressed his intention to take responsibility for any harm caused, will remain in an executive role to manage compensation-related matters, it added.
Kobayashi's red yeast rice supplements are regulated under a system created in 2015 under former premier Shinzo Abe.
Some watchdogs have reportedly expressed concerns that the regulation of these products is not sufficiently stringent and that they do not always have the advertised effects.
D.Sawyer--AMWN